



## NEWS RELEASE

Media Contacts:  
Danielle Halstrom  
Wyeth Pharmaceuticals  
(484) 865-2020

Investor Contact:  
Justin Victoria  
Wyeth  
(973) 660-5340

Douglas Petkus  
Wyeth  
(973) 660-5218

### **Wyeth Announces Recipients of the Soozie Courter "Sharing a Brighter Tomorrow" Hemophilia Scholarship Program**

#### *Program Marks Continued Commitment to Education and Assistance to Hemophilia Community*

**Collegeville, Pa., September 29, 2009** — Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the recipients of the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program for the 2009 – 2010 academic year. The Program aims to provide financial assistance for higher education to individuals with hemophilia. Since 2002, Wyeth has donated nearly \$700,000 in scholarship monies through the Program.

For the 2009 – 2010 academic year, the Program will award \$50,000 in scholarships to students in the hemophilia community, including five \$4,000 graduate scholarships and twelve \$2,500 undergraduate scholarships. To be eligible for the scholarships, students must have either hemophilia A or



hemophilia B and be a high school senior, have a high school diploma or graduate equivalency diploma (GED), or be currently enrolled in an accredited junior college, college (undergraduate or graduate), or vocational school.

“Wyeth recognizes the role of higher education in achieving the hemophilia community’s goal of developing the next generation of leaders, and is proud to provide scholarships to students across the country,” says Angela Rossetti, Assistant Vice President, and Global Business Manager for Wyeth Hemophilia. “The Soozie Courter Scholarship Program allows us to simultaneously give back to the hemophilia community while also honoring the program’s namesake – a clinical research specialist who was passionate about improving the lives of patients with hemophilia.”

Recipients of this year’s five graduate scholarships include: Alex Nester (Vermillion, SD), Claire Powell (Colorado Springs, CO), John McNeil (Charlottesville, VA), Benjamin Murphy (Baltimore, MD), and Seth Balkanyi (Columbus, OH). Recipients of this year’s 12 undergraduate scholarships include: Cecilio Velasco (Washington, DC), Daniel Warren (Carrollton, VA), David Kober (Monmouth Junction, NJ), Michael Deeb (Wynantskill, NY), Andrew Deeb (Wynantskill, NY), Grant Hiura (Daly City, CA), Raymond Sowinski (Beaver Falls, PA), Eric Shepard (Brookville, OH), Tristan Stoch (Keyport, WA), Daniel Musher (Bethesda, MD), Timothy Hildebrand (Lititz, PA), and Gabriel Johnston (Mount Vernon, WA).



### **About Soozie Courter**

The Program is named in honor of Soozie G. Courter (1955–1999), a valued and respected friend of the hemophilia community for more than fifteen years. During her career in the pharmaceutical industry, Courter worked primarily on hemophilia product development. Courter was director of Genetics Institute’s Hemophilia Clinical Program from 1994 to 1999, during which time Genetics Institute was acquired by Wyeth. By naming its scholarship fund in honor of Courter, Wyeth aims to recognize her many contributions to the hemophilia community, particularly her compassion and interest in issues related to the advancement of hemophilia research.

### **Wyeth and Hemophilia**

Wyeth works to help improve the health of hemophilia patients through its products, education, patient assistance programs and by supporting associations throughout the world. For more information on Wyeth, hemophilia, and the Soozie Courter “Sharing a Brighter Tomorrow” Hemophilia Scholarship Program, visit [www.hemophiliavillage.com](http://www.hemophiliavillage.com), a site that serves as a resource for patients, parents, and caregivers in the hemophilia community.



## About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

*The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory*



*approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-*

**Wyeth**

*looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.*

#####

258868-01